BIOXCEL THERAPEUTICS INC
NASDAQ: BTAI (BioXcel Therapeutics, Inc.)
Kemas kini terakhir: 16 jam lalu0.074
-0.04 (-37.11%)
| Penutupan Terdahulu | 0.118 |
| Jumlah Dagangan | 47,480,718 |
| Harga / Jualan (P/S) | 3.40 |
| Julat 52 Minggu |
| Margin Operasi (TTM) | -6,011.31% |
| EPS Cair (TTM) | -11.12 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | -71.10% |
| Nisbah Semasa (MRQ) | 1.48 |
| Aliran Tunai Operasi (OCF TTM) | -66.36 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -48.95 M |
| Pulangan Atas Aset (ROA TTM) | -52.46% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Drug Manufacturers - Specialty & Generic (US) | Bercampur | Menaik |
| Drug Manufacturers - Specialty & Generic (Global) | Bercampur | Menaik | |
| Stok | BioXcel Therapeutics, Inc. | Bercampur | Menurun |
AISkor Stockmoo
| Konsensus Penganalisis | NA |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | 3.0 |
| Purata Bergerak Teknikal | 0.0 |
| Osilator Teknikal | -2.5 |
| Purata | 0.17 |
|
BioXcel Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on drug development utilizing novel artificial intelligence (AI) to identify the next wave of medicines across neuroscience and immuno-oncology. The pipeline products of the company are-BXCL501, being evaluated as a potential treatment for agitation associated with multiple neurological disorders and BXCL701, an investigational oral innate immune activator for the treatment of aggressive forms of prostate cancer and other solid and liquid tumors. The company's commercial product, IGALMI (developed as BXCL501) is a proprietary, sublingual film formulation of dexmedetomidine approved by the FDA for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults. |
|
| Sektor | Healthcare |
| Industri | Drug Manufacturers - Specialty & Generic |
| Gaya Pelaburan | Small Value |
| % Dimiliki oleh Orang Dalam | 8.65% |
| % Dimiliki oleh Institusi | 11.02% |
Pemilikan
| Nama | Tarikh | Syer Dipegang |
|---|---|---|
| Oaktree Fund Advisors, Llc | 30 Jun 2026 | 245,585 |
| &Partners | 30 Jun 2026 | 83,588 |
Tiada data dalam julat masa ini.
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2026 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |